Waste Management WM

Reference table

1. What the business is, and the acquisition that reshaped it

Waste Management provides collection, transfer, disposal, recycling and — since November 2024 — medical-waste and secure-information-destruction services across North America and, newly, internationally. Approximately 60,500 employees, chief executive James C. Fish Jr., NYSE-listed since 1988, beta 0.437.

The Stericycle acquisition is the organising fact of the last two years. From the 10-K's risk factors: "Our November 2024 acquisition of Stericycle increased our exposure to international jurisdictions, primarily Western Europe, and we are subject to laws and regulations in the U.S. and internationally concerning transportation, management and disposal or destruction of medical waste streams, including regulations that govern the definition, generation, segregation, handling, packaging, transportation, treatment, storage and disposal or destruction of medical waste and controlled substances waste... Additionally, our secure information destruction services are subject to laws and regulations regarding proper handling and protection of personal and confidential information."

cf_a records acquisitionsNet of −$7,488M in FY2024 against −$92M in FY2023 and −$395M in FY2025. The 10-Q confirms Stericycle "is now presented as our Healthcare Solutions segment."

The revenue-line evidence is unambiguous: the vendor's seg_prod block shows Healthcare Solutions at $403M in FY2024 and $2,951M in FY2025 — a $2,548M step, essentially the whole of the $3,141M year-on-year revenue increase.

Revenue and the deceleration:

Note the line that matters: FY2025 revenue rose 14.2% and diluted EPS FELL, from $6.81 to $6.70. The bridge is visible in the same table — interest expense rose $314M (+52.5%) and, per inc_a, depreciation rose $463M (+19.3%) on the acquired asset base — so the acquired revenue arrived carrying its financing and its depreciation and did not, in its first full year, add to earnings per share. That is what a $7.5 billion debt-funded acquisition looks like in year one, and it is the reason the stock has done nothing.

2. The quarterly record — three quarters of deceleration and a volume disclosure

Four readings.

The deceleration is monotonic and it is the Stericycle comparison rolling off: +19.0%, +14.9%, +7.1%, +3.5%, +3.9%. The current 3.9% is the underlying rate, and consensus wants +5.5% in the September quarter.

Revenue has missed in three of the last four quarters — Q3 2025 ($6,443M vs $6,492M), Q4 2025 ($6,313M vs $6,387M), Q1 2026 ($6,227M vs $6,279M) and Q2 2026 ($6,684M vs $6,709M). Earnings beat in three of five. That is the signature of a company hitting its cost targets and missing its demand assumptions.

Margins are holding but not expanding: operating margin 18.75% in the June quarter against 18.46% a year earlier, and 18.28% for FY2025 against 18.81% for FY2024. The FY2025 margin decline is Stericycle arriving at lower margins; the recent quarterly improvement is the synergy programme.

The GAAP-to-adjusted gap is small and shrinking: $1.80 vs $1.92, $1.49 vs $1.98, $1.83 vs $1.93, $1.79 vs $1.81, $1.95 vs $2.02. The Q3 2025 gap of $0.49 (33%) was integration cost; the current gap of $0.07 (3.6%) is nearly nothing. That is a genuinely favourable signal and it is stated as one: the adjustments are ending, which means the reported and underlying pictures are converging.

The two disclosures that define the medium-term question

On volumes, from the 10-Q's operating-cost discussion, verbatim:

> "The increase in fuel costs was primarily due to the increases in average market prices for diesel fuel previously mentioned. This increase was partially offset by reduced fuel consumption due to declines in collection volumes."

On Healthcare Solutions, verbatim:

> "Our Healthcare Solutions segment generated income from operations in the three months ended June 30, 2026 and a loss from operations in the six months ended June 30, 2026. The improvement across both time periods is primarily due to non-recurring integration costs incurred during the prior year periods along with lower costs in the current year from the realization of synergies, offset by lower volumes."

Read those two together and the situation is precise. Volumes are declining in the core collection business AND in the acquired medical-waste business. The earnings are being produced by price escalators and by cost removal. That is a perfectly legitimate way to grow earnings and it has a natural end point.

On the cost side the news is genuinely good, and it is the offsetting fact:

> "Selling, general and administrative expenses decreased for the three months ended June 30, 2026, as compared to the prior year period, primarily due to decreases in professional fees and lower labor costs resulting from synergies achieved from our acquisitions, particularly Stericycle, partially offset by higher bad debt expenses."

> "The decrease in labor and related benefits costs for the three months ended June 30, 2026... was primarily due to a reduction in workforce as we achieved synergies from our acquisitions, particularly Stericycle, and lower annual incentive compensation costs."

Note the one cautionary detail inside the good news: "higher bad debt expenses" appears in both the three-month and six-month SG&A discussions, and "increases in bad debt expenses" is named first among the drivers of the six-month increase. Rising bad debt in a waste business is a customer-quality signal and it is worth watching.

3. Cash flow, leverage and the restarted buyback

Capex and free cash flow — checked first, and the result is CLEAN on the arithmetic with one field defect alongside it.

Free cash flow is computed by subtraction and the arithmetic is correct in all four years. capexToDepreciationTTM of 0.9552 is comfortably positive with no zero-capex, negative-capex or added-back signature; capexToRevenueTTM of 11.5% is consistent with a heavy-asset waste business; freeCashFlowYieldTTM of 3.97% reconciles to the per-share fields ($16.20 operating cash flow less $7.318 capex equals $8.881 of free cash flow per share, times ~399.7M shares equals $3,550M, a 3.94% yield on the market capitalisation). No correction is applied to free cash flow.

But cf_a's depreciation field changes basis between FY2024 and FY2025 — running at roughly 60% of the income-statement figure for three consecutive years and then 105% in the fourth. This is the MCK/ADP defect class: the same field carrying two different definitions in adjacent years. It does not affect the free-cash-flow calculation, which uses capex, but it makes any multi-year depreciation or EBITDA reconstruction from cf_a unreliable, and the income-statement series is used throughout this dive.

A limitation that must be stated: WM's filings were extracted WITHOUT tables. All six documents carry "tables": false. The 10-Q contains the sentence "Our calculation of free cash flow and reconciliation to net cash provided by operating activities for the three and six months ended June 30, 2026 and 2025 is shown in the table below" — and the table is absent from the extracted text. The company's own free-cash-flow figure for the June quarter is therefore not available to this dive, nor are the volume and yield percentages WM publishes each quarter, nor the segment income statements. Every filing-sourced figure below is quoted from narrative prose, and the gaps are reported as gaps.

Leverage:

Two things to note. capitalLeaseObligations is reported as zero and totalDebt equals short-term plus long-term debt exactly — so the lease double-count test does not apply here and is recorded as not applicable rather than passed. And $201 million of cash on $25.2 billion of revenue is eight days' worth; this is a business that runs on its revolver and commercial paper, which the 10-K confirms: "We have $2.9 billion of debt as of December 31, 2025 that is exposed to changes in market interest rates within the next 12 months, associated with our commercial paper borrowings and tax-exempt bonds."

The 10-K's own leverage warning, verbatim, because it is the sharpest sentence in the filing:

> "An important factor in our credit ratings is our leverage. If we do not achieve our projected reduction in leverage following our acquisition of Stericycle, it could negatively impact our credit ratings. If we were unable to maintain our investment grade credit ratings in the future, our interest expense would increase and our ability to obtain financing on favorable terms could be adversely affected."

And a second, which explains the capital-allocation sequencing: "If economic conditions or other risks and uncertainties cause a significant reduction in our cash flows from operations, we may reduce or suspend capital expenditures, growth and acquisition activity, implementation of our business strategy, dividend declarations or share repurchases."

The buyback restarted — and the payload does not know

From the 10-Q, verbatim:

> "During the three months ended June 30, 2026, we repurchased 3.0 million shares of our common stock in open market transactions... for $671 million, inclusive of per-share commissions and taxes, for a weighted average price per share of $223.94. During the six months ended June 30, 2026, we repurchased 4.5 million shares of our common stock... for $1.0 billion... for a weighted average price per share of $227.89. These repurchases were made under the $3.0 billion Board of Directors authorization announced in December 2025. As of June 30, 2026, the Company has remaining authorization for $2.0 billion of future share repurchases."

The vendor's cf_a reports commonStockRepurchased of ZERO for FY2025, following −$262M in FY2024, −$1,302M in FY2023 and −$1,500M in FY2022. So the payload correctly records the suspension and has no record of the December 2025 authorisation or of the $1.0 billion actually spent in the first half of 2026.

Note that the weighted average repurchase price of $227.89 for the half and $223.94 for the quarter both sit within 1.2% of today's $225.25 — management has been buying at exactly this level. That is a mild positive and it is worth naming: it is the only signal in the file about what the people who see the volume data think the stock is worth.

4. Segments — the product block does not tie and the geography block has lost the United States

seg_prod FY2025 sums to 120.5% of revenue — the block is GROSS of intercompany eliminations and the elimination line is missing.

Three problems and they compound. First, the FY2025 sum is 120.5% of revenue — Waste Management reports lines of business gross and eliminates roughly $5.2 billion of intercompany revenue (a landfill charges a collection route for disposal), and the elimination line is absent from the block, so the individual lines cannot be read as revenue contributions. Second, the FY2024 sum is 98.0%, so the block's basis changed between years and the growth rates in the third column above are therefore not reliable and are shown only to demonstrate the discontinuity — note the implausible +55.2% for Landfill and +90.4% for Transfer. Third, the WM Renewable Energy line, present at $273M in FY2023 and $318M in FY2024, DISAPPEARED in FY2025, so the one genuinely optionality-bearing business in this company cannot be sized from the payload at all.

seg_geo FY2025 contains ONE line and it is Canada — REJECTED outright.

The United States line — 96% of this company — is simply missing from the most recent year, exactly as it was on NEM. The block ties to within 0.5% in every prior year and then loses the domestic line in the year a reader would use. Note also the mangled key names, "U [S]" and "C [A]", which are corrupted country-code tags. No geographic analysis appears in this dive.

What the filing supplies instead, in narrative: Healthcare Solutions is the Stericycle business and "increased our exposure to international jurisdictions, primarily Western Europe" — so the international share is materially higher than the 3.8% the block implies, and it is not measurable from this archive because the segment tables were stripped.

5. Valuation — priced in or room?

At $225.25 (market cap $90.04B, ~399.7M shares):

Estimate coverage is good through FY2028 — 16, 17 and 9 analysts on EPS — and thin at FY2029 (3). The FY2029 row is excluded from every conclusion. The FY2027 EPS range is $8.679 to $9.605, a 10.7% spread — narrow, as befits a utility-like business, and it means the fair-value work here is almost entirely about the multiple.

est.ebitdaAvg and est.ebitAvg are REJECTED — fixed-ratio fabrication, every forward year. ebitdaAvg is exactly 28.08% of revenueAvg in FY2026, FY2027, FY2028, FY2029 and FY2030; ebitAvg is exactly 16.94% in every one. As on MRSH in this same batch, the fabricated EBITDA ratio happens to sit close to the truth — FY2025 actual EBITDA of $7,201M on $25,204M is a 28.57% margin — which is precisely what makes it dangerous. A number that is accidentally accurate is still fabricated. All forward valuation uses epsAvg. Seventeenth consecutive name.

Peer set is a market-capitalisation cohort with two genuine comparables. CTAS, EMR, ITW, JCI, MMM, NOC, RSG, TDG, UPS, WCN. Republic Services and Waste Connections are the direct peers and both are present; the rest are unrelated industrials. The payload carries no peer earnings estimates, so no multiple comparison is computed and none is asserted from memory.

5a. What today's price assumes (the inversion)

At $225.25 — 27.7x FY2026 consensus, 24.8x FY2027, a 3.97% free-cash-flow yield — the price embeds:

• Adjusted EPS of $8.12 in 2026 and $9.09 in 2027. (Consensus; 16 and 17 analysts.) The first half delivered $3.83 ($1.81 + $2.02), so FY2026 needs $4.29 in the second half against $3.91 in the second half of 2025 — a 9.7% improvement, with the Q3 consensus of $2.18 against $1.98 implying +10.1%. That requires the synergy run rate to hold and revenue to accelerate.
• Revenue growth reaccelerates to +5.5% in Q3 and +4.8% for the full year. (Consensus.) The last three quarters delivered +7.1%, +3.5% and +3.9%, and revenue MISSED in three of the last four. This is the most fragile assumption in the price, because it requires the volume declines the 10-Q discloses to stop, and there is no evidence in this archive that they have.
• Stericycle synergies continue to expand the margin. (Company disclosure via the 10-Q's SG&A and labour-cost commentary, half-weighted.) SG&A fell year on year in the quarter; operating margin was 18.75% against 18.46%. Roughly 400-600 basis points of the consensus earnings growth above revenue growth is this, and synergy programmes have finite lives.
• Leverage falls and the credit rating holds. (Company disclosure, half-weighted; the 10-K names the risk directly.) Net debt of $22,706M is 3.03x EBITDA against $201M of cash. Interest expense rose 52.5% in FY2025; a downgrade would raise it again.
• The market keeps paying 24-28x forward earnings. (Our number.) At 22x FY2027E the stock is $200; at 28x it is $254. WM has historically commanded a premium multiple for its defensiveness, and 24.8x is at the lower end of the range it has occupied — which is either the opportunity or the market's judgement about the volume line.

5b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as: EPS growth (+11.9%, from FY2026E $8.121 to FY2027E $9.087) + multiple drift (MODEST EXPANSION; our base of $240 is 26.4x FY2027E against 24.8x today, +6.5%) + shareholder yield (+3.8%: 2.2% buyback at the current pace and a 1.57% dividend) ≈ +20% if the re-rating comes and roughly +16% if it does not.

Our base assumes a modest multiple expansion and we name it as the fragile leg. The argument for it: this is a 0.437-beta, contractual, price-escalating business with irreplaceable assets that has de-rated because of a single acquisition, and the integration is visibly working on cost. The argument against it: a business with declining volumes, 3.03x leverage and a loss-making acquired segment does not obviously deserve a premium multiple, and the market has had twelve months to reach that conclusion.

Note the composition: roughly 12 points of earnings growth, roughly 4 points of shareholder yield, and roughly 6 points of hoped-for re-rating. If the multiple simply holds, the return is about 16% and the fair value is about $226 — spot. That is the honest downside of the base case and it is why this is a Watch rather than a Buy: the earnings-plus-yield return is decent, and none of it requires us to be right about anything the market has not already seen.

5c. Variant perception (where we differ, what would surprise)

• On the level we are 1.6% below the street's $244 and 6.5% above spot, so we have no meaningful variant perception — and the street's number here is not usable anyway. The pt block reports targetHigh = $244, targetLow = $244, targetConsensus = $244 and targetMedian = $244. Four fields, one number. On a name with 35 covering analysts in the grades block, a price-target distribution with zero dispersion is not a consensus; it is a single estimate that the payload has replicated across four fields. We report $244 as the street figure with that caveat attached and we place no weight on the implied unanimity.
• Where we do differ from the consensus earnings path is on the revenue line, and we think the risk is to the downside. Consensus wants +4.8% revenue growth in FY2026 and +5.3% in FY2027. The last four quarters delivered +14.9%, +7.1%, +3.5% and +3.9%, and revenue missed the estimate in three of them. The 10-Q's own language — "declines in collection volumes" and, for Healthcare Solutions, "lower volumes" — says the underlying unit demand is shrinking, and price escalators have a ceiling. Watchable number: revenue in the 2026-10-26 print against the $6,800M consensus, which implies +5.5%.
• We think the ending of the adjustment gap is being under-noticed and it is a positive. GAAP-to-adjusted EPS ran $0.49 apart in Q3 2025 and $0.07 apart in Q2 2026 — a 3.6% adjustment. The reported and underlying pictures have converged, which means the Stericycle integration costs are essentially finished, and that is a cleaner base for FY2027 than the headline multiples suggest.
• Positive surprise that would force a re-rate: collection volumes turning positive, or Healthcare Solutions posting revenue growth rather than merely lower costs; or net debt to EBITDA below 2.75x with the buyback continuing past the $2.0 billion remaining authorisation, which would resolve the 10-K's own credit-rating concern.
• Negative surprise that would break the thesis: revenue growth below 3% in the September quarter; Healthcare Solutions returning to an operating loss; a credit-rating action; rising bad-debt expense continuing to be named in the SG&A discussion, which is a customer-quality signal; or a large acquisition before leverage normalises, given that the 10-Q notes the company "remain[s] in the measurement period for our 2026 acquisitions."

Synthos fair values

All three anchors are multiples of the FY2027 consensus EPS distribution (mean $9.087, low $8.679, high $9.605, 17 analysts), cross-checked against FY2026 and the free-cash-flow and dividend yields.

• Bear ~$190 — 21.9x the FY2027 consensus LOW of $8.679. Cross-check: 23.4x FY2026E; 3.4% below the 52-week low of $196.77; a 1.86% dividend yield. The scenario: collection volumes keep falling, price escalators cannot cover it, Stericycle synergies are exhausted without revenue growth, leverage does not fall, and the market re-rates a low-growth leveraged industrial to a low-growth industrial multiple. −15.6%.
• Base ~$240 — 26.4x the FY2027 consensus MEAN of $9.087. Cross-check: 29.6x FY2026E; 24.2x FY2028E; 2.6% below the 52-week high of $246.51; a 1.48% dividend yield. The scenario: revenue growth stabilises around 4-5%, synergies deliver the consensus margin expansion, leverage falls toward 2.75x, the buyback continues at roughly $2 billion a year, and the multiple recovers modestly toward the middle of the range this franchise has occupied. +6.5%.
• Bull ~$290 — 30.2x the FY2027 consensus HIGH of $9.605. Cross-check: 29.3x FY2028E; 17.6% above the 52-week high. The scenario: volumes turn, Healthcare Solutions grows rather than shrinks, WM Renewable Energy becomes a disclosed and separately valued business, leverage normalises, and the market restores the premium defensive multiple this company carried before the acquisition. +28.8%.

Base is 6.5% above spot; asymmetry 1.85:1 (15.6% down, 28.8% up), plus a 3.8% shareholder yield. That is genuinely close to the Tactical bar and it does not clear it: this programme requires roughly 2:1 with named triggers, and the base case additionally requires a multiple expansion we have named as fragile. Watch, with the trigger price stated in Section 8.

6. Knowledge base — empty, and instructively so

Raw hits: 146. After a case-sensitive entity re-run: 1. Entity matches: ZERO. Used: 0. Discarded: 146.

The sweep ran entity terms WM, Waste Management, Stericycle, RSG, Republic Services and Waste Connections, plus free text on waste, landfill and recycling, across the full distilled claim store.

Not one claim in the store names Waste Management — or Republic Services, or Waste Connections, or Stericycle. The single case-sensitive survivor is a free-text match with an empty entity list:

> 2020-03-25 · bearish · conviction 55 · horizon: principle · entities: (none) · channel: joscha_bach

> "~80% of the economy produces 'landfill' or documents transactions; its main product is financial 'casino tokens' — much activity is non-essential to survival."

That is a philosophical claim about economic productivity in which "landfill" is a metaphor for worthless output. It is discarded on content, not on entity, and it is exactly the kind of claim that would have read as substantive if a keyword sweep had been trusted.

The 145 discards are pure free-text noise across 43 channels and they divide into three amusing but instructive families. "Waste" as in wasted time, wasted capital and wasted energy — macrovoices (15), luke_gromen (10), forward_guidance (6) and two dozen others. "Waste" as in metabolic and cellular waste — rhonda_patrick (5), david_sinclair (4), peter_attia (1) and huberman_lab (1) supply eleven hits about autophagy and cellular waste clearance, none of which is about a company. "Recycling" as in capital recycling and debt recycling. And "WM" as a two-letter substring, which is why the case-sensitive entity discipline is mandatory rather than optional on this name.

Conclusion. Breadth 0, claim count 0, net conviction NONE. The lane is EMPTY and is reported as empty rather than padded, consistent with the treatment of CSX and JCI. Conviction contributes exactly zero to this verdict.

Logged for the ingest side, and it is the second such finding in this batch: the entire North American environmental-services sector — Waste Management, Republic Services, Waste Connections, Casella, Clean Harbors, roughly $200 billion of combined market capitalisation — has ZERO entity coverage in this knowledge base. The identical finding was recorded on insurance brokerage (Marsh, Aon, Willis Towers Watson, Arthur J. Gallagher, Brown & Brown) in this same batch. Two entire defensive-industrial sectors are invisible to the store, which is a coverage question rather than a defect and should be raised as one.

7. Data integrity — what we rejected and why

Eight findings.

1. The entire price-target block is a single number replicated four times — FLAGGED, not used. pt reports targetHigh $244, targetLow $244, targetConsensus $244, targetMedian $244. A distribution with zero dispersion across 35 covering analysts (per the grades block: 20 buy, 15 hold, 0 sell) is not a consensus. It is one estimate, and the four fields create a false impression of agreement. We quote $244 as the street figure with the caveat attached, note that it implies +8.3%, and place no weight on the implied unanimity. Compare COF in an earlier dive, where a genuine 57-analyst distribution ran $229 to $300.

2. seg_geo FY2025 contains ONLY a Canadian line — the United States is ABSENT. REJECTED. The block reports "C [A]" $967M and nothing else, 3.8% of $25,204M of revenue. Every prior year ties: FY2022 100.0%, FY2023 99.9%, FY2024 99.5%. The domestic line — 96% of the company — vanished in the most recent year. This is the NEM defect class exactly (NEM named the United Kingdom as its largest geography with the United States absent). Note also the corrupted key names, "U [S]" and "C [A]", which are mangled country-code tags. No geographic analysis appears in this dive.

3. seg_prod FY2025 sums to 120.5% of revenue and the basis changed between years — REJECTED for growth analysis. The eight FY2025 lines total $30,362M against $25,204M of revenue; the FY2024 lines total $21,617M against $22,063M (98.0%). The FY2025 block is gross of intercompany eliminations (a landfill charges a collection route for disposal) and the elimination line is missing; the FY2024 block is not, or is eliminated differently. The consequence is that the year-on-year growth rates the block appears to support — Landfill +55.2%, Transfer +90.4% — are artefacts of a basis change, not business events, and they are shown in Section 4 only to demonstrate the discontinuity. Separately, the WM Renewable Energy line ($273M in FY2023, $318M in FY2024) DISAPPEARED in FY2025, so the company's one genuine optionality-bearing business cannot be sized from this payload.

4. cf_a depreciation changes basis between FY2024 and FY2025 — the MCK/ADP defect class. cf_a depreciationAndAmortization runs $1,284M / $1,326M / $1,472M for FY2022-FY2024 against income-statement figures of $2,150M / $2,201M / $2,400M — approximately 60% in each year — and then $3,005M against $2,863M (105%) in FY2025. The field carries two different definitions in adjacent years. It does not affect the free-cash-flow calculation, which uses capex, but any multi-year depreciation or EBITDA reconstruction from cf_a is unreliable, and the income-statement series is used throughout this dive.

5. Capex and free cash flow — CHECKED AND CLEAN. FY2025 operating cash flow $6,043M less capex $3,227M equals free cash flow $2,816M; the subtraction is correct in all four years. capexToDepreciationTTM 0.9552 (positive, plausible for a heavy-asset waste business); capexToRevenueTTM 11.5%; the per-share fields reconcile ($16.20 − $7.318 = $8.881, × ~399.7M = $3,550M, a 3.94% yield against the vendor's stated 3.968%). The free-cash-flow yield stands as reported and no correction is applied. Note that this is a real check on a name the brief flagged as capital-intensive and therefore high-risk for the capex defect; it came back clean.

6. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED. ebitdaAvg is exactly 28.08% of revenueAvg and ebitAvg exactly 16.94% in all five forward years. As on MRSH in this same batch, the fabricated ratio sits close to the FY2025 actual EBITDA margin of 28.57% — so it looks right, which is why it is dangerous. All forward valuation uses epsAvg, and the FY2029 row (3 analysts) is excluded from every conclusion.

7. returnOnEquityTTM is present in km_ttm (0.2892) and ABSENT from ratios_ttm — seventeenth name running. The km_ttm figure of 28.92% is used, with the note that on $9,990M of equity supporting $45,835M of assets (financial leverage 4.68x) and with tangible book value NEGATIVE, return on equity is close to meaningless here. returnOnInvestedCapitalTTM of 9.01% and returnOnCapitalEmployedTTM of 11.75% are the informative figures and both are used in preference.

8. stockBasedCompensationToRevenueTTM is 0, and cf_a reports stockBasedCompensation of 0 for FY2025 after $118M (FY2024), $93M (FY2023) and $84M (FY2022). A company that granted $118M of stock compensation in 2024 did not grant zero in 2025, and the insider file contains A-Award grants dated 2026-05-20. The field is used nowhere. Note also cf_a commonStockRepurchased of 0 for FY2025, which is correct — the buyback was suspended — but which the payload has not updated for the December 2025 authorisation or the $1.0 billion actually spent in the first half of 2026 (see finding below).

Corporate actions absent from the payload — THREE, all found in the filings. (a) A $3.0 billion share repurchase authorisation announced in December 2025, under which $671M was repurchased in Q2 2026 (3.0M shares at $223.94) and $1.0 billion in the half (4.5M shares at $227.89), leaving $2.0 billion at 2026-06-30. (b) An executive reshuffle disclosed in the 8-K of 2026-05-13: Rafael E. Carrasco, SVP Enterprise Strategy and President of WM Healthcare Solutions, gave notice on 2026-05-08 of his retirement effective 2026-07-17 after leading the Stericycle acquisition and integration; and Tara J. Hemmer was promoted to Executive Vice President and Chief Operating Officer, reporting to President John J. Morris Jr., who "voluntarily resigned from the position of Chief Operating Officer." (c) The annual meeting of 2026-05-12, at which 345,284,283 of 402,913,509 outstanding shares were represented. None appears in any vendor field.

Enterprise value — CHECKED AND CLEAN. enterpriseValueTTM of $112,835M against a rebuild of market cap $90,036M + total debt $22,907M − cash $201M + minority interest $1M = $112,743M. A 0.08% residual — the tightest EV reconciliation in this batch. EV/EBITDA of 14.97x is used as reported.

Filings extracted WITHOUT tables — stated, not worked around. All six WM documents carry "tables": false. The 10-Q explicitly refers to a free-cash-flow reconciliation table that is absent from the extracted text; the segment income statements, the volume and yield percentages WM publishes each quarter, and the balance-sheet and cash-flow statements are likewise absent. Every filing-sourced figure in this dive is quoted from narrative prose. The consequences: the company's own free-cash-flow figure for the June quarter is unavailable, the magnitude of the volume decline cannot be quantified, and the rejected segment blocks could not be replaced from the filing. These are gaps and they are reported as gaps.

Quote versus technical blocks — minor 52-week disagreement. quote.yearHigh/yearLow report $248.13 / $194.11; tech.hi52/lo52 report $246.51 / $196.77. Differences of 0.7% and 1.4%. tech is used throughout. Note also that tech.max_dd_from_peak (−8.624%) is identical to tech.pct_from_hi, so the deepest drawdown in the measured window is the current one.

Non-equity tripwire — checked and passed. Common stock, NYSE-listed. Price $225.25; beta 0.437; volume 2.87M shares (~$646M of turnover); 52-week band $196.77-$246.51, a 25% range — the narrowest in this batch, consistent with the lowest beta. This is common equity.

8. Technicals, insiders and verdict

Technicals

• Price $225.25, 0.2% BELOW the 50-day moving average of $225.62 and 0.9% above the 200-day average of $223.29. The three numbers are within 1.1% of each other — the flattest configuration in this batch and a precise picture of a stock that has stopped moving.
• −8.6% from the 52-week high of $246.51; +14.5% above the low of $196.77. Position in the annual range: 57th percentile.
• RSI 40.8 — the second-softest reading in this batch. MACD +0.40 — effectively zero.
• Maximum drawdown from peak in the measured window: −8.6%, identical to the current distance from the high — the shallowest in this batch and consistent with a 0.437 beta.
• Relative performance, and it is uniform: 3-month −1.1% vs SPY +7.6%; 6-month +0.9% vs SPY +11.1%; 12-month −1.6% vs SPY +24.3% and QQQ +30.8%. A 26-point twelve-month deficit, and negative at two of three horizons. This is the only name in this batch with a negative absolute return at both the three-month and twelve-month horizons.
• Sentiment: 20 buy, 15 hold, 0 sell across 35 analysts; consensus label Buy. Price target $244 across all four fields — see Section 7, finding 1.

Today's move. WM closed DOWN 0.52% at $225.25 from $226.43, opening at $224.53 and trading $222.16 to $226.05 on 2.87M shares — a quiet down day. No company-specific filing is dated 2026-08-04; the last was the 2026-07-28 results 8-K.

The honest read on the entry: it is neutral in the most literal possible sense. Price within 0.2% of the 50-day average, within 0.9% of the 200-day, RSI at 41, MACD at zero, twelve-month return of −1.6%. There is neither a discount nor an extension. What there is, is a business the market has stopped paying a premium for, and a decision about whether that is right.

Insiders — mechanical, with one exercise-and-sell

The file contains a mixture of option exercises, tax withholdings and awards. The one discretionary transaction is Rafael Carrasco, SVP of Enterprise Strategy, who on 2026-06-05 exercised 2,655 options at $126.005 and sold the same 2,655 shares at $220.465 the same day, retaining 15,540 — a same-day exercise-and-sell with no retention.

Context the filings supply and the insider block does not: Carrasco gave notice on 2026-05-08 of his retirement effective 2026-07-17, per the 8-K of 2026-05-13, which describes him as having led "the Stericycle, Inc. acquisition and the successful integration and development of the Company's healthcare solutions business." A retiring executive monetising in-the-money options a month after announcing his departure is routine and carries no signal, and we say so rather than counting it as a bearish insider sale.

The remaining transactions are A-Award grants dated 2026-05-20 to Marcel Dalby (SVP Business Optimisation & Collection, 2,257 shares) and Tara J. Hemmer (EVP & Chief Operating Officer, holding 81,461 after) — the latter consistent with her promotion announced 2026-05-13.

There is not one open-market purchase in the file, and no discretionary sale by a continuing executive. The insider file is signal-free and is reported as such. The most informative "insider" transaction is not in this block at all: the company itself bought 4.5 million shares in the first half at a weighted average of $227.89 — 1.2% above today's price.

Verdict

Watch.

The arithmetic. At $225.25 Waste Management trades at 27.7x the FY2026 consensus of $8.121 and 24.8x FY2027's $9.087, for consensus earnings growth of 11.9% — a forward PEG of 2.67. Our base fair value of $240 is 6.5% above spot with 1.85:1 asymmetry ($190 bear, $290 bull), plus a 3.8% shareholder yield. The base case requires a 6.5% multiple expansion and that is named as its fragile leg; without it the stock is worth roughly spot.

What is genuinely good. One of the most defensive business models in the index — 0.437 beta, contractual revenue with price escalators, landfill permits regulators will not issue again, an 18.75% operating margin and a 35.0% gross margin. The Stericycle synergies are working and the filing says so plainly: SG&A FELL year on year on lower professional fees and a reduction in workforce. The GAAP-to-adjusted gap has collapsed from $0.49 (Q3 2025) to $0.07 (Q2 2026), so the integration costs are essentially finished. The buyback restarted — $671M in the quarter, $1.0 billion in the half, $2.0 billion of authorisation remaining — at a weighted average price of $227.89, within 1.2% of today's price. And free cash flow, the field most often corrupt in this feed, is verified correct at $2,816M for FY2025.

What keeps it at Watch rather than Buy.

First, volumes are declining and the filing says so twice. "[R]educed fuel consumption due to declines in collection volumes" and, for Healthcare Solutions, "lower volumes." Revenue growth has decelerated for three consecutive quarters — +14.9%, +7.1%, +3.5%, +3.9% — and revenue MISSED the estimate in three of the last four quarters, while consensus wants +5.5% in the September quarter. A fixed-cost network with falling volume is the exact configuration that has taken UPS's operating income down 39% in three years, elsewhere in this batch.

Second, the earnings growth is entirely cost. Consensus needs 400-600 basis points of margin-driven growth above a 5% revenue line, sourced from a synergy programme with a finite life.

Third, leverage is elevated by choice and the company has warned about it. Net debt $22,706M, 3.03x EBITDA, $201M of cash — eight days of revenue — and the 10-K's own words: "If we do not achieve our projected reduction in leverage following our acquisition of Stericycle, it could negatively impact our credit ratings." Interest expense rose 52.5% in FY2025 and was the principal reason EPS fell on 14.2% revenue growth.

Fourth, the asymmetry is 1.85:1 against a 2:1 requirement, and the base case needs a re-rating.

Fifth, the knowledge base is empty and the street's price-target block is one number in four fields.

Pre-registered KILL criteria — what would take this to Hold or Avoid:

• Revenue growth below 3% in any quarter, i.e. the deceleration continuing past the Stericycle anniversary.
• Healthcare Solutions returning to an operating loss for a full quarter, after producing one for the six months to June 2026.
• A credit-rating downgrade or an outlook change, which the 10-K identifies as the specific consequence of failing to delever.
• Net debt to EBITDA above 3.25x, or the buyback suspended again to protect the rating.
• Rising bad-debt expense named for a third consecutive quarter in the SG&A discussion — a customer-quality signal already appearing in both the three-month and six-month commentary.
• A large acquisition before leverage normalises.

Pre-registered UPGRADE conditions — what would take this to Buy — Tactical:

• A price below roughly $205, which is 22.6x FY2027E and restores asymmetry to better than 2.3:1 with the same base case, without requiring any multiple expansion. This is the operative trigger and it is a price, not a date.
• Collection volumes turning positive, which is the single fact that would change the growth score and the multiple together.
• Healthcare Solutions posting revenue growth rather than cost reduction, which would begin to justify the $7.5 billion paid.
• Net debt to EBITDA below 2.75x with the buyback continuing, resolving the 10-K's own stated concern.
• WM Renewable Energy restored to a disclosed revenue line and sized, so the one non-linear asset in this company can be valued.

Where WM fits in the Synthos Framework Portfolio. No position today; a named limit. This is a genuinely high-quality, low-beta, irreplaceable-asset business trading at the low end of its own multiple range for identifiable and partly finite reasons — and it has a volume problem that the price does not reflect. A 1.5% starter at roughly $205, scaling to 3% on two consecutive quarters of stable-or-positive collection volumes. Buying at 24.8x forward on a shrinking volume base because the chart is flat is not a thesis. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $225.25, with the fair-value anchors, kill criteria and the $205 trigger all gradeable.

Single biggest risk: declining collection volumes. The 10-Q states it in two separate places — lower fuel consumption "due to declines in collection volumes", and Healthcare Solutions improving on cost but "offset by lower volumes." Waste Management's revenue is currently growing because prices escalate and because an acquisition was absorbed, not because there is more waste to collect. Price escalators have ceilings; synergy programmes have end dates; a route network sized for a larger volume does not shrink gracefully. At 24.8x FY2027 consensus with 3.03x leverage and negative tangible book value, the price assumes the volume line stabilises. The archive contains no evidence that it has, and the tables that would have quantified it were stripped in extraction — which is itself worth stating rather than assuming away.

Provenance & disclosures

• Traceability: ZERO knowledge-base claims name Waste Management (raw hits 146, case-sensitive survivors 1, entity matches 0, used 0, discarded 146; breadth 0, claim count 0, net conviction NONE). The lane is reported as EMPTY rather than padded, consistent with the treatment of CSX and JCI. The single case-sensitive survivor — joscha_bach, 2020-03-25, bearish 55, empty entity list — is "~80% of the economy produces 'landfill' or documents transactions; its main product is financial 'casino tokens'", a philosophical claim in which landfill is a metaphor, discarded on content. The 145 discards span 43 channels and three noise families: "waste" as wasted time or capital (macrovoices 15, luke_gromen 10, forward_guidance 6 and others); "waste" as METABOLIC waste — rhonda_patrick (5), david_sinclair (4), peter_attia (1) and huberman_lab (1) supply eleven hits about cellular waste clearance; and "WM" as a two-letter substring, which is why the case-sensitive entity discipline is mandatory on this name. Not one claim names Republic Services, Waste Connections or Stericycle either. Logged for the ingest side, and this is the SECOND such finding in this batch: the entire North American environmental-services sector (~$200bn of combined market capitalisation) has zero entity coverage in this store, exactly as insurance brokerage does. Conviction contributes exactly zero to this verdict.
• Data as-of: fundamentals — annual statements through 2025-12-31 from the 10-K filed 2026-02-09; quarterly results, the repurchase disclosure, the volume and synergy commentary and the Healthcare Solutions result through 2026-06-30 from the 10-Q filed 2026-07-29 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873602 = 2026-08-04T20:00:02Z ($225.25, −0.52%; 50-DMA $225.62; 200-DMA $223.29; RSI 40.8; MACD +0.40) · knowledge-base claims 2026-08-04. The fiscal year is the calendar year. All figures come from the Synthos vendor data file for WM or from the SEC filings in the WM archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents and a limitation that must be stated: 10-K filed 2026-02-09 (fiscal 2025 — the source of the leverage warning, the Stericycle regulatory disclosure and the free-cash-flow definition); 10-Q filed 2026-04-29 (March 2026 quarter); 10-Q filed 2026-07-29 (June 2026 quarter — the source of the volume disclosures, the SG&A and labour-cost commentary, the Healthcare Solutions result and the repurchase detail); 8-K filed 2026-05-13 (Item 5.02 — Rafael E. Carrasco's retirement notice of 2026-05-08 effective 2026-07-17, and Tara J. Hemmer's promotion to EVP and COO with John J. Morris Jr. "voluntarily resign[ing] from the position of Chief Operating Officer"); 8-K filed 2026-05-14 (annual-meeting results; 402,913,509 shares outstanding at 2026-05-12); 8-K filed 2026-07-28 (second-quarter results; Exhibit 99.1 not extracted). ALL SIX DOCUMENTS WERE EXTRACTED WITHOUT TABLE PRESERVATION ("tables": false). The 10-Q explicitly refers to a free-cash-flow reconciliation table that is absent from the text; the segment income statements, the quarterly volume and yield percentages, and the balance-sheet and cash-flow statements are likewise absent. Every filing-sourced figure in this dive is quoted from narrative prose. The company's own free-cash-flow figure for the June quarter is unavailable, the magnitude of the volume decline cannot be quantified, and the rejected segment blocks could not be replaced from the filing. These are gaps and they are reported as gaps.
• Where the vendor was REJECTED: the entire pt block, which reports targetHigh = targetLow = targetConsensus = targetMedian = $244 — a single estimate replicated across four fields on a name with 35 covering analysts; quoted with the caveat and given no weight. seg_geo FY2025, which contains only a Canadian line of $967M, 3.8% of revenue, with the UNITED STATES ABSENT ENTIRELY — the NEM defect class — against 100.0%, 99.9% and 99.5% ties in the three prior years, with corrupted key names ("U [S]", "C [A]"). seg_prod FY2025, whose eight lines sum to $30,362M against $25,204M of revenue (120.5%) because the intercompany elimination line is missing, while the FY2024 block ties at 98.0% — a basis change between years that makes the apparent growth rates (Landfill +55.2%, Transfer +90.4%) artefacts rather than events — and from which the WM Renewable Energy line ($273M FY2023, $318M FY2024) DISAPPEARED in FY2025. cf_a depreciationAndAmortization, which runs at ~60% of the income-statement figure for FY2022-FY2024 and 105% in FY2025 — the MCK/ADP two-definitions-in-adjacent-years class; the income-statement series is used throughout. est.ebitdaAvg/ebitAvg, exactly 28.08% and 16.94% of revenueAvg in all five forward years — and dangerous precisely because the fabricated ratio sits close to the FY2025 actual EBITDA margin of 28.57% — all forward valuation uses epsAvg, and the FY2029 row (3 analysts) is excluded. returnOnEquityTTM present in km_ttm (0.2892) and absent from ratios_ttm; the km_ttm figure is used, with returnOnInvestedCapitalTTM of 9.01% preferred as informative given negative tangible book. stockBasedCompensationToRevenueTTM and cf_a stockBasedCompensation, both 0 for FY2025 after $118M in FY2024, contradicted by A-Award grants in the insider file; used nowhere. quote.yearHigh/yearLow ($248.13/$194.11) differ from tech.hi52/lo52 ($246.51/$196.77) by 0.7% and 1.4%; tech is used.
• Where the vendor was CLEAN and it is recorded: capital expenditure and free cash flow — FY2025 operating cash flow $6,043M less capex $3,227M equals free cash flow $2,816M, subtraction correct in all four years, capexToDepreciationTTM of 0.9552 positive and plausible, per-share fields reconciling to a 3.94% yield against the vendor's stated 3.968%; a real check on a name the brief flagged as high-risk for the capex defect, and it came back clean. And enterpriseValueTTM of $112,835M against a rebuild of $112,743M — a 0.08% residual, the tightest EV reconciliation in this batch.
• Corporate actions absent from the payload — THREE: the $3.0 billion share repurchase authorisation announced December 2025, under which $671M was repurchased in Q2 2026 (3.0M shares at $223.94) and $1.0 billion in the half (4.5M shares at $227.89), leaving $2.0 billion at 2026-06-30 — against cf_a reporting ZERO repurchase for FY2025; the executive reshuffle of 2026-05-13 (Carrasco's retirement, Hemmer's promotion to EVP and COO, Morris's voluntary resignation from the COO role while remaining President); and the annual meeting of 2026-05-12.
• Estimate coverage: 16 analysts on FY2026 EPS, 17 on FY2027 — the anchor for all three fair values, with a range of $8.679 to $9.605, a 10.7% spread and the narrowest of any name in this batch after MRSH; 9 on FY2028; 3 on FY2029, excluded from every conclusion.
• Peer note: the vendor peer set — CTAS, EMR, ITW, JCI, MMM, NOC, RSG, TDG, UPS, WCN — correctly contains both direct comparables (Republic Services, Waste Connections) alongside eight unrelated industrials. The payload carries no peer earnings estimates, so no multiple comparison is computed and none is asserted.
• Fair-value caveat: the $190 / $240 / $290 anchors are multiples of the FY2027 consensus EPS distribution — 21.9x the low of $8.679, 26.4x the mean of $9.087, and 30.2x the high of $9.605 — cross-checked against FY2026 and FY2028 estimates, against the 52-week range and against the dividend yield. Stated arithmetic, not a discounted cash flow. The base case REQUIRES an approximately 6.5% multiple expansion from 24.8x to 26.4x and this is named as the fragile leg of the return bridge; if the multiple simply holds, the fair value is approximately $226 — spot — and the return is earnings growth plus a 3.8% shareholder yield.
• Basis note: consensus estimates and earn_cal epsActual are on an adjusted basis excluding Stericycle integration costs. The gap between GAAP diluted EPS and reported adjusted EPS has narrowed from $0.49 in Q3 2025 (33%) to $0.07 in Q2 2026 (3.6%), which is recorded as a favourable signal: the adjustments are essentially finished. Forward multiples use the adjusted basis; the 31.8x trailing multiple uses the vendor's trailing GAAP per-share figure and is not comparable to them.
• Timing: second-quarter results were released 2026-07-28, seven days before this dive, and beat consensus adjusted EPS by 2.0% ($2.02 against $1.98) while MISSING revenue by 0.4% ($6,684M against $6,709M) — the third revenue miss in four quarters. The next print is 2026-10-26, 83 days away, against consensus of $2.18 in EPS and $6,800M of revenue. The most recent insider transaction is dated 2026-06-05 and is a same-day exercise-and-sell by an executive who had announced his retirement four weeks earlier. 2026-08-04 carried no company-specific filing.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.